a-Synuclein in Transgenic Models of MSA

$351,369P01FY2011NSNIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications & trials

Paper 38468536 Paper 36442207 Paper 36102173 Paper 34739766 Paper 33755181 Paper 32206478 Paper 32025029 Paper 32011643 Paper 31706219 Paper 31621598 Paper 31515103 Paper 31456212 Paper 31327626 Paper 31122601 Paper 30170741 Paper 29293269 Paper 29254663 Paper 29246926 Paper 29089869 Paper 28476636 Paper 28236005 Paper 28202694 Paper 28086964 Paper 28057080 Paper 27859565 Paper 27606342 Paper 27422051 Paper 27374978 Paper 26924723 Paper 26749150 Paper 26740557 Paper 26494242 Paper 26394760 Paper 26388203 Paper 26369944 Paper 26341908 Paper 26201615 Paper 26025783 Paper 25981961 Paper 25966683 Paper 25909086 Paper 25886309 Paper 25803611 Paper 25763826 Paper 25483980 Paper 25448247 Paper 25428949 Paper 25211238 Paper 25041866 Paper 25033770 Paper 25019582 Paper 25009275 Paper 24909319 Paper 24698767 Paper 24662516 Paper 24597842 Paper 24525765 Paper 24507091 Paper 24477673 Paper 24462903 Paper 24361600 Paper 24310907 Paper 24304186 Paper 23867236 Paper 23761114 Paper 23729158 Paper 23708963 Paper 23665165 Paper 23463005 Paper 23384597 Paper 23313024 Paper 23254192 Paper 23218087 Paper 23122955 Paper 23029293 Paper 23015436 Paper 23013868 Paper 22993288 Paper 22817712 Paper 22795533 Paper 22677718 Paper 22526019 Paper 22508489 Paper 22421352 Paper 22357716 Paper 22314685 Paper 22281106 Paper 22229117 Paper 22228725 Paper 22211740 Paper 22150925 Paper 22127477 Paper 21962754 Paper 21801874 Paper 21624403 Paper 21559417 Paper 21482928 Paper 21045796 Paper 20942898 Paper 20547476

Abstract

Multiple system atrophy (MSA) is a progressive, degenerative neurological disorder characterized by parkinsonism, ataxia &dysautonomia. The cardinal pathological feature of MSA is the presence of glial cytoplasmic inclusions composed of alpha-synuclein (SYN) in oligodendrocytes. Recent studies suggest that abnormal SYN accumulation in neurons &glia leads to cellular dysfunction &neurodegeneration. During the previous funding period we developed in vitro &in vivo models of MSA showing that mitochondrial damage &hyperphosphorylated SYN aggregate generation may contribute to the pathogensis of MSA. However, mechanisms by which these pathways promote oligodendrogial dysfunction &neurodegeneration are unclear. In this renewal we will investigate the role of mitochondrial dysfunction in SYN phosphorylation &toxicity. Our central hypothesis is that oxidative stress due to mitochondrial dysfuntion may promote G-protein coupled receptor kinase (GRK) activation &toxic SYN phosphorylation. The main objective is to investigate neurodegeneration in MSA-like SYN transgenic (tg) models to determine if reducing SYN accumulation represents a therapeutic strategy for MSA. Aim 1. In order to determine the role of hyperphosphorylated SYN accumulation in oligodendrocj^es in the mechanisms of neurotoxicity, we will analyze SYN accumulation &neurodegeneration in myelin basic protein (MBP)-SYN tg mice expressing wild-type (wt) human SYN or a nonphosphorylatable SYN mutant (S129A). MBP-SYNwt tg mice will be crossed with GRK2- or GRKS-deficient mice &MBP-SYNwt tg mice &MBP-SYN(S129A) tg mice will receive intra-cerebral infections with lentivirus expressing GRK2 or GRK5 under a oligodendroglial specific promoter (MBP). Aim 2. In order to determine the role of mitochondrial dysfunction &oxidative stress on GRK activation &SYN phosphorylation, MBP-SYN (wt and S129A) mice &oligodendroglial cells will be challenged with 3- nitropropionic acid. Aim 3. In order to determine if neuronal impairments in MSA models can be ameliorated by reducing SYN aggregation or inhibiting GRKs, MBP-SYN wt tg mice will be treated with rifampicin or GRK blockers. Behavioral performance, neurodegeneration, SYN oligomerization &phosphorylation &GRK activity will be assessed

View original record on NIH RePORTER →